OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
AIMD$1.7556

Ainos Inc

Biotechnology & Medical ResearchVerified

Ainos Inc has a market capitalization of $12.72 million and a price-to-book ratio of 1.68, indicating that the market values the company at a premium to its book value. The company's liquidity position is characterized by a current ratio of 1.06, suggesting limited short-term liquidity cushion. With only $417,350 in cash and equivalents and $11 million in long-term debt, the company's net cash position is negative, raising concerns about its ability to meet long-term obligations without additional financing. Profitability metrics reveal significant challenges for Ainos Inc. The company reported a net loss of $14.77 million and an operating loss of $13.99 million in the latest period. Return on equity (ROE) is -195.32%, and return on assets (ROA) is -7.08%, both far below industry norms. The gross profit margin of 82.9% is strong, but this is insufficient to offset the company's high operating expenses. Geographic and segment exposure data is not available in the provided dataset, but the company's revenue concentration appears to be limited to a single business line given the absence of disclosed segments. This lack of diversification increases vulnerability to sector-specific risks. Growth prospects are constrained by the company's financial performance. Revenue of $124.16 million in the latest period is offset by a net loss of $14.77 million. The company's free cash flow is negative at -$10.04 million, and capital expenditures of -$34,560 suggest minimal investment in growth infrastructure. Analysts have recorded a last actual revenue of $134 million, indicating some level of revenue stability despite the net loss. The company's risk profile is elevated by its negative net cash position and high debt-to-equity ratio of 1.45. While dilution risk is currently assessed as low, the company's operating cash flow of -$4.61 million and free cash flow of -$10.04 million suggest potential future financing needs that could lead to share dilution. No recent events or filings are disclosed in the provided dataset, but the company's financial performance and liquidity position warrant close monitoring.

30-day price · AIMD(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyAinos Inc
TickerAIMD.O
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
AI analysis

Business. Ainos Inc is a biotechnology and medical research company focused on pharmaceuticals and medical research.

Classification. Ainos Inc is classified under the Healthcare economic sector, Pharmaceuticals & Medical Research business sector, and Biotechnology & Medical Research industry with 92% confidence.

Ainos Inc has a market capitalization of $12.72 million and a price-to-book ratio of 1.68, indicating that the market values the company at a premium to its book value. The company's liquidity position is characterized by a current ratio of 1.06, suggesting limited short-term liquidity cushion. With only $417,350 in cash and equivalents and $11 million in long-term debt, the company's net cash position is negative, raising concerns about its ability to meet long-term obligations without additional financing. Profitability metrics reveal significant challenges for Ainos Inc. The company reported a net loss of $14.77 million and an operating loss of $13.99 million in the latest period. Return on equity (ROE) is -195.32%, and return on assets (ROA) is -7.08%, both far below industry norms. The gross profit margin of 82.9% is strong, but this is insufficient to offset the company's high operating expenses. Geographic and segment exposure data is not available in the provided dataset, but the company's revenue concentration appears to be limited to a single business line given the absence of disclosed segments. This lack of diversification increases vulnerability to sector-specific risks. Growth prospects are constrained by the company's financial performance. Revenue of $124.16 million in the latest period is offset by a net loss of $14.77 million. The company's free cash flow is negative at -$10.04 million, and capital expenditures of -$34,560 suggest minimal investment in growth infrastructure. Analysts have recorded a last actual revenue of $134 million, indicating some level of revenue stability despite the net loss. The company's risk profile is elevated by its negative net cash position and high debt-to-equity ratio of 1.45. While dilution risk is currently assessed as low, the company's operating cash flow of -$4.61 million and free cash flow of -$10.04 million suggest potential future financing needs that could lead to share dilution. No recent events or filings are disclosed in the provided dataset, but the company's financial performance and liquidity position warrant close monitoring.
Key takeaways
  • Ainos Inc has a negative net income of $14.77 million and a negative return on equity of -195.32%.
  • The company's liquidity position is weak, with a current ratio of 1.06 and negative net cash after subtracting total debt.
  • Despite a strong gross profit margin of 82.9%, the company's operating and net losses indicate significant cost overruns.
  • The company's market capitalization of $12.72 million is significantly lower than its enterprise value to revenue multiple of 187.65.
  • Ainos Inc has a high debt-to-equity ratio of 1.45, indicating a leveraged capital structure.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$124.2k
Gross profit$102.9k
Operating income-$14.0M
Net income-$14.8M
R&D
SG&A
D&A
SBC
Operating cash flow-$4.6M
CapEx-$34.6k
Free cash flow-$10.0M
Total assets$20.9M
Total liabilities$13.3M
Total equity$7.6M
Cash & equivalents$417.4k
Long-term debt$11.0M
Valuation
Market price$1.75
Market cap$12.7M
Enterprise value$23.3M
P/E
Reported non-GAAP P/E
EV/Revenue187.7
EV/Op income
EV/OCF
P/B1.7
P/Tangible book1.7
Tangible book$7.6M
Net cash-$10.6M
Current ratio1.1
Debt/Equity1.4
ROA-70.8%
ROE-2.0%
Cash conversion31.0%
CapEx/Revenue-27.8%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 693 companies
MetricAIMDActivity
Op margin-11268.0%2.4% medp25 -91.8% · p75 12.5%bottom quartile
Net margin-11896.8%1.2% medp25 -98.4% · p75 10.4%bottom quartile
Gross margin82.9%45.6% medp25 29.8% · p75 66.7%top quartile
CapEx / revenue-27.8%-5.2% medp25 -15.8% · p75 -1.7%bottom quartile
Debt / equity145.0%9.3% medp25 0.1% · p75 43.8%top quartile
Observations
IR observations
Last actual EPS-57.00 USD
Last actual revenue134,000.00 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-16 23:55 UTC#7b71309b
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 07:22 UTCJob: cc0789be